Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2015 08:00 ET | Source: Innocoll Holdings plc

Innocoll to Report Second Quarter 2015 Financial Results and Host Webcast and Conference Call on August 14, 2015

ATHLONE, Ireland, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of...
July 01, 2015 07:00 ET | Source: Innocoll Holdings plc

Innocoll AG Appoints Jose Carmona as Chief Financial Officer

Appointment is effective on September 1, 2015 Gordon Dunn will continue as Vice President, Finance Director, Europe ATHLONE, Ireland, July 1, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL)...
June 30, 2015 07:00 ET | Source: Innocoll Holdings plc

Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation for Cogenzia for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection

ATHLONE, Ireland, June 30, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
June 17, 2015 16:05 ET | Source: Innocoll Holdings plc

Innocoll AG to Present at JMP Securities Healthcare Conference

ATHLONE, Ireland, June 17, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
June 15, 2015 07:00 ET | Source: Innocoll Holdings plc

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-2 Phase 3 Study for the Treatment of Diabetic Foot Infection

ATHLONE, Ireland, June 15, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
May 15, 2015 07:00 ET | Source: Innocoll Holdings plc

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-1 Phase 3 Study for the Treatment of Diabetic Foot Infection

ATHLONE, Ireland, May 15, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
May 14, 2015 07:00 ET | Source: Innocoll Holdings plc

Innocoll AG Announces First Quarter Financial and Operating Results

ATHLONE, Ireland, May 14, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
May 07, 2015 16:30 ET | Source: Innocoll Holdings plc

Innocoll to Report First Quarter 2015 Financial Results and Host Webcast and Conference Call on May 14, 2015

ATHLONE, Ireland, May 7, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of...
April 24, 2015 08:00 ET | Source: Innocoll Holdings plc

Innocoll AG Announces Pricing of Follow-On Offering

ATHLONE, Ireland, April 24, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a specialty pharmaceutical company, today announced the pricing of its follow-on public offering of 3,321,669 American...
April 01, 2015 07:00 ET | Source: Innocoll Holdings plc

Pivotal Pharmacokinetic Study of Innocoll's XaraColl(R) Supports Use of 300 mg Dose for Phase 3 Clinical Studies in Post-Operative Pain

ATHLONE, Ireland, April 1, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right